Cannabidiol Oral Solution in Pediatric Participants With Treatment-resistant Seizure Disorders
- First Posted Date
- 2014-12-24
- Last Posted Date
- 2017-06-23
- Lead Sponsor
- INSYS Therapeutics Inc
- Target Recruit Count
- 61
- Registration Number
- NCT02324673
- Locations
- 🇺🇸
University of California San Francisco Medical Center, San Francisco, California, United States
🇺🇸Miami Children's Hospital, Miami, Florida, United States
🇺🇸Child Neurology Center - NW F, Pensacola, Florida, United States
Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Lennox-Gastaut Syndrome
- Conditions
- Lennox-Gastaut Syndrome
- Interventions
- Drug: Placebo Solution
- First Posted Date
- 2014-12-17
- Last Posted Date
- 2018-01-04
- Lead Sponsor
- INSYS Therapeutics Inc
- Registration Number
- NCT02318537
Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder
- First Posted Date
- 2014-12-17
- Last Posted Date
- 2018-07-26
- Lead Sponsor
- INSYS Therapeutics Inc
- Target Recruit Count
- 52
- Registration Number
- NCT02318602
- Locations
- 🇺🇸
University of California San Francisco Medical Center, San Francisco, California, United States
🇺🇸Miami Children's Hospital, Miami, Florida, United States
🇺🇸Child Neurology Center - NW F, Pensacola, Florida, United States
Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Dravet Syndrome
- Conditions
- Dravet Syndrome
- Interventions
- Drug: Placebo Solution
- First Posted Date
- 2014-12-17
- Last Posted Date
- 2018-01-04
- Lead Sponsor
- INSYS Therapeutics Inc
- Registration Number
- NCT02318563
Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe Pain
- Conditions
- Post-operative Pain
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-12-08
- Last Posted Date
- 2017-08-09
- Lead Sponsor
- INSYS Therapeutics Inc
- Target Recruit Count
- 40
- Registration Number
- NCT02310581
Study to Explore Effectiveness of Sublingual Fentanyl Spray in Emergency Department Patients With Acute Pain
- Conditions
- Acute Pain
- Interventions
- Drug: Placebo Sublingual SprayDrug: Intravenous Placebo
- First Posted Date
- 2014-05-14
- Last Posted Date
- 2017-07-05
- Lead Sponsor
- INSYS Therapeutics Inc
- Registration Number
- NCT02137525
- Locations
- 🇺🇸
Maricopa Medical Center, Phoenix, Arizona, United States
🇺🇸Olive View-UCLA Medical Center, Sylmar, California, United States
🇺🇸Kansas University Medical Center, Kansas City, Kansas, United States
Fentanyl Sublingual Spray for the Treatment of Acute Procedure-related Pain in a Monitored Setting
- Conditions
- Chronic Pain
- Interventions
- Drug: Placebo Sublingual Spray (PSS)
- First Posted Date
- 2014-05-14
- Last Posted Date
- 2018-01-04
- Lead Sponsor
- INSYS Therapeutics Inc
- Registration Number
- NCT02138409
Exploratory Bioavailability of Fentanyl Sublingual Spray Under Fasting Conditions
- Conditions
- Bioavailability
- Interventions
- First Posted Date
- 2014-05-14
- Last Posted Date
- 2014-12-12
- Lead Sponsor
- INSYS Therapeutics Inc
- Target Recruit Count
- 12
- Registration Number
- NCT02138396
- Locations
- 🇺🇸
Worldwide Clinical Trials Early Phase Services, LLC, San Antonio, Texas, United States
A Study of the Abuse Potential of Dronabinol in Recreational Cannabinoid Users
- Conditions
- Drug Abuse, Medication
- Interventions
- First Posted Date
- 2014-03-24
- Last Posted Date
- 2014-05-13
- Lead Sponsor
- INSYS Therapeutics Inc
- Target Recruit Count
- 43
- Registration Number
- NCT02094599
- Locations
- 🇨🇦
INC Research Toronto, Inc., Toronto, Ontario, Canada
Possible New Therapy for Advanced Cancer
- Conditions
- Adrenocortical Carcinoma
- Interventions
- Drug: IL-13-PE
- First Posted Date
- 2013-04-16
- Last Posted Date
- 2015-04-27
- Lead Sponsor
- INSYS Therapeutics Inc
- Target Recruit Count
- 9
- Registration Number
- NCT01832974
- Locations
- 🇺🇸
National Cancer Institute at the National Institutes of Health, Bethesda, Maryland, United States